Efficacy and Safety Study of Short-term Antibiotic for Pyelonephritis in Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urinary tract community infections are one of very frequent reason consultation and prescription. Urinary tract represents the second site of bacterial community infection after the respiratory system. The management of the acute uncomplicated pyelonephritis was simply codified in the past recommendations of the French Agency for Safety Health Products (AFSSAPS) in 2008. Treatment is based on two main families of antibiotics, fluoroquinolones with 7 days treatment and 3rd generation cephalosporins with 10 to 14 days treatment.

The practice of a short treatment with ceftriaxone intra venous relayed by cefixime orally provides a simplified treatment for patients, a reduced use of fluoroquinolones and a probable decrease in correlation with the emergence of fluoroquinolones resistance, and finally, a decrease in the cost of treatment of acute uncomplicated pyelonephritis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old

NCT00136656

Pyelonephritis

COMPLETED PHASE4

Cefuroxime Resistance in Pyelonephritis

NCT04616352

Urinary Tract Infections

COMPLETED

Pharmacological Study of High Doses of Ceftriaxone in Meningitidis

NCT01745679

Meningitis Neurological Infections

COMPLETED PHASE4

Short-term Antibiotic Therapy for Pyelonephritis in Childhood

NCT00724256

Pyelonephritis

TERMINATED PHASE3

Prolonged Infusion Cefepime and Nosocomial Infections

NCT02568800

Urinary Tract Infection Respiratory Tract Infection

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.

The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria.

Clinical, biological and radiological data will gathered during this consultation :

* Clinical data: flank pain, fever, urinary symptoms,
* Biological data: urine dipstick (BU No. 1), cytobacteriological urinary (ECBU No. 1), blood prélèvements (Blood count, creatinine, CRP)
* Imagery: renal and bladder ultrasound. During the next consultations in the emergency department, respectively on day 3 (J3) of treatment and on day 9 (J9), urine tests (urinary dipsticks \[BU No. 2 and No. 3\] and cytobacteriological urinary \[ECBU No. 2 and No. 3\] will be realised. The clinical and biological management of patient will be performed by the same department to ensure a better comparability of biological results and a centralized real-time clinical data.

Patient follow-up will end with a phone call on day 37 (J37), and the rate of clinical relapses and / or biological occurred between day 9 and day 37.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Uncomplicated Pyelonephritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ceftriaxone

Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.

The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women between 18 and 65 years old
* Diagnosis of Acute Uncomplicated Pyelonephritis
* Patient obliged to participate in the French national health and pensions system.
* Patient who have read, understood and signed the consent

Exclusion Criteria

* Women who are pregnant
* Men
* One of these risk factor who define a complicated pyelonephritis:

Medical history of uro-nephrology problem Nephropathy Obstructive Uropathy Vesicoureteral reflux Post mictinal residue \> 100mL Urinary fistula Catheter vesicle and urethral Kidney transplantation Immunodeficiency Diabetes

* Recurrent pyelonephritis
* Allergy of betalactam or cephalosporin
* History of hypersensitivity reactions to antibiotic medications
* Patient in terminal care
* Trouble of cognitive function
* Patient deprive of judicial or administrative freedom
* Patient participating to another trial
* Refusal to participate to the trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No